Ensysce Common Stock vs Long Term Debt Analysis
ENSC Stock | USD 0.58 0.03 4.90% |
Ensysce Biosciences financial indicator trend analysis is much more than just examining Ensysce Biosciences latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ensysce Biosciences is a good investment. Please check the relationship between Ensysce Biosciences Common Stock and its Long Term Debt accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ensysce Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.
Common Stock vs Long Term Debt
Common Stock vs Long Term Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ensysce Biosciences Common Stock account and Long Term Debt. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Ensysce Biosciences' Common Stock and Long Term Debt is -0.27. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of Ensysce Biosciences, assuming nothing else is changed. The correlation between historical values of Ensysce Biosciences' Common Stock and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of Ensysce Biosciences are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Common Stock i.e., Ensysce Biosciences' Common Stock and Long Term Debt go up and down completely randomly.
Correlation Coefficient | -0.27 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Common Stock
Long Term Debt
Long-term debt is a debt that Ensysce Biosciences has held for over one year. Long-term debt appears on Ensysce Biosciences balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Ensysce Biosciences balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.Most indicators from Ensysce Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ensysce Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ensysce Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.At present, Ensysce Biosciences' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 3.22, whereas Issuance Of Capital Stock is forecasted to decline to about 8.5 M.
2023 | 2024 (projected) | Interest Income | 98.6K | 93.6K | Tax Provision | 281.2K | 373.2K |
Ensysce Biosciences fundamental ratios Correlations
Click cells to compare fundamentals
Ensysce Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Ensysce Biosciences fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 196.5M | 351.8K | 16.4M | 5.9M | 2.7M | 2.6M | |
Total Current Liabilities | 2.8M | 7.0M | 16.5M | 9.5M | 3.3M | 6.2M | |
Total Stockholder Equity | 186.2M | (6.4M) | (8.2M) | (4.0M) | (651.3K) | (618.7K) | |
Retained Earnings | 2.5M | (56.0M) | (85.8M) | (110.9M) | (121.6M) | (115.5M) | |
Cash | 1.1M | 194.2K | 12.3M | 3.1M | 1.1M | 1.1M | |
Other Assets | 5K | 3.8K | 754.8K | 585.9K | 527.3K | 500.9K | |
Cash And Short Term Investments | 1.1M | 194.2K | 12.3M | 3.1M | 1.1M | 1.1M | |
Common Stock Shares Outstanding | 98.3K | 68.8K | 84.0K | 179.9K | 2.3M | 3.9M | |
Long Term Debt Total | 566.3K | 791.3K | 4.4M | 140.2K | 161.2K | 153.1K | |
Liabilities And Stockholders Equity | 196.5M | 351.8K | 16.4M | 5.9M | 2.7M | 2.6M | |
Capital Surpluse | 2.9M | 2.5M | 78.0M | 107.2M | 123.3M | 129.5M | |
Total Liab | 10.3M | 7.0M | 24.6M | 9.9M | 3.4M | 3.2M | |
Total Current Assets | 1.2M | 347.9K | 15.7M | 5.3M | 2.3M | 2.2M | |
Short Term Debt | 2.6M | 4.3M | 12.7M | 4.3M | 854.7K | 812.0K | |
Common Stock | 181.2M | 1.6K | 2.5K | 642.0 | 315.0 | 299.25 | |
Other Current Liab | 2.8M | 856.0K | 3.4M | 2.3M | 542.3K | 515.1K | |
Net Debt | (494.9K) | 4.1M | 483.4K | 1.3M | (268.9K) | (255.5K) | |
Accounts Payable | 540.8K | 1.7M | 301.1K | 2.9M | 1.9M | 1.4M | |
Non Current Assets Total | 195.3M | 3.9K | 754.8K | 585.9K | 419.2K | 398.3K | |
Non Currrent Assets Other | (351.0) | 3.8K | (24.7B) | 558.7K | 419.2K | 440.2K | |
Non Current Liabilities Total | 7.6M | 6.8M | 8.1M | 450.5K | 26.4K | 25.1K | |
Other Current Assets | 138.6K | 153.7K | 3.4M | 2.2M | 1.2M | 1.3M | |
Other Stockholder Equity | 2.5M | 49.5M | 77.7M | 106.9M | 120.9M | 127.0M |
Pair Trading with Ensysce Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ensysce Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ensysce Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving together with Ensysce Stock
0.62 | EVOK | Evoke Pharma | PairCorr |
Moving against Ensysce Stock
0.74 | LLY | Eli Lilly Earnings Call This Week | PairCorr |
0.73 | VKTX | Viking Therapeutics | PairCorr |
0.73 | OGN | Organon | PairCorr |
0.68 | HCWB | HCW Biologics | PairCorr |
0.68 | KRYS | Krystal Biotech Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Ensysce Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ensysce Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ensysce Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ensysce Biosciences to buy it.
The correlation of Ensysce Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ensysce Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ensysce Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ensysce Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ensysce Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for Ensysce Stock analysis
When running Ensysce Biosciences' price analysis, check to measure Ensysce Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ensysce Biosciences is operating at the current time. Most of Ensysce Biosciences' value examination focuses on studying past and present price action to predict the probability of Ensysce Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ensysce Biosciences' price. Additionally, you may evaluate how the addition of Ensysce Biosciences to your portfolios can decrease your overall portfolio volatility.
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |
Is Ensysce Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ensysce Biosciences. If investors know Ensysce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ensysce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.69) | Revenue Per Share 0.985 | Quarterly Revenue Growth (0.64) | Return On Assets (1.56) | Return On Equity (13.20) |
The market value of Ensysce Biosciences is measured differently than its book value, which is the value of Ensysce that is recorded on the company's balance sheet. Investors also form their own opinion of Ensysce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ensysce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ensysce Biosciences' market value can be influenced by many factors that don't directly affect Ensysce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ensysce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ensysce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ensysce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.